Summary
Nine adult patients with Ki-1-positive largecell anaplastic lymphoma were treated with MACOP-B. Two suffered from relapsed disease and had previously received chemotherapy; a third patient had received a single dose of 100mg/m2 cisplatin before initiation of MACOP-B. The stage of lymphoma was determined according to the Ann Arbor Conference criteria and was II in one, III in two and IV in six patients. All patients had constitutional symptoms. Five patients had achieved complete remission 4 weeks after termination of the protocol and there were two partial remissions. One patient died of massive pulmonary embolism during the 4th week of treatment; another patient, who had received MACOP-B as salvage therapy, died of progressive lymphoma 1 month after completion of the regimen. Maximal observed toxicities according to WHO were mucositis grade 3 (n=3) and there were three cases with thromboembolic complications, including a fatal pulmonary embolism in a young patient. However, MACOP-B appears an effective, fairly well-tolerated and feasible therapy for patients with Ki-1-positive large-cell anaplastic lymphoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- MACOP-B:
-
methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin, cotrimoxazole
- LCAL:
-
large-cell anaplastic leukemia
References
Barrios H, Weiss PD (1987) Toxicity of MACOP-B for aggressive lymphoma in elderly patients. Blood 70:242a
Bruyn CC de, Jogessar VB, Cooper K (1990) Large cell anaplastic Ki-1 positive Lymphoma. A study of 5 cases (abstract). Fourth International Conference on Malignant Lymphoma, Lugano June 6–9, 1990. p 54
Bucksy P, Feller AC, Reiter A, Heitger A, Gadner H, Riehm (1990) Malignant histiocytosis and large cell anaplastic (Ki-1) lymphoma in children and adolescent-preliminary experience of the BFM study group (abstract). Fourth International Conference on Malignant Lymphoma, Lugano June 6–9, 1990. p 35
Carbone PP, Kaplan HS, Mushoff K et al. (1971) Report of the committee on Hodgkin's disease staging. Cancer Res 31:1860–1861
Chott A, Kaserer K, Augustin I, Vesely M, Heinz R, Oelinger W, Hanak H, Radaszkiewicz T (1990) Ki-1-positive large cell lymphoma. A clinical study of 41 cases. Am J Surg Pathol 14:439–448
Coleman M, Gerstein G, Topilow A, Lebowicz J, Bernhardt B, Chiarieri D, Silver RT, Pasmantier MW (1987) Advances in chemotherapy for large cell lymphoma. Semin Hematol 24 [Suppl 1]:8–20
Connors JM, Klimo P (1987) Minimizing toxicity of MACOP-B (letter) J Clin Oncol 5:1302–1303
Connors JM, Klimo P (1988) MACOP-B chemotherapy for malignant lymphomas and related conditions: 1987 update and additional observations. Semin Hematol 25 [Suppl 2]:41–46
Fisher RI, Hubbard SM, De Vita Jr et al. (1981) Factors predicting long-term survival in diffuse mixed, histiocytic or undifferentiated lymphoma. Blood 58:45–51
Goldie JH, Coldman AJ, Gudauskas GA (1982) Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 66:439–449
Greer JP, Kinney MC, Collins RD, Salhany KE, Wolff SN, Hainsworth JD, Flexner JM, Stein RS (1991) Clinical features of 31 patients with Ki-1 anaplastic large-cell lymphoma. J Clin Oncol 9:539–547
Hoane BR, Shields AF, Porter BA, Shulman HM (1991) Detection of lymphomatous bone marrow involvement with magnetic resonance imaging. Blood 78:728–738
Ibrahim EM, Satti MB, Al-Idrissi HY, Al-Mulhim, Abssod GH, Jabar AA (1988) Non-Hodgkin's lymphoma in Saudi Arabia: prognostic factors and an analysis of the outcome of combination chemotherapy only, for both localized and advanced disease. Eur J Cancer Clin Oncol 24:391–401
Klimo P, Connors JM (1985) MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 102:596–602
Klimo P, Connors JM (1987) Updated clinical experience with MACOP-B, Semin Hematol 24 [Suppl 1]:26–34
Le Beau MM, Bitter MA, Larson RA, Doane LA, Ellis Ed, Franklin WA, Rubin CM, Kadin ME, Vardiman JW (1989) The t(2;5)-(p23;q35): a recurring chromosomal abnormality in Ki-1-positive anaplastic large cell lymphoma. Leukemia 3:866–870
Löwenthal DA, White A, Koziner B, Straus DJ, Lee BJ, Clarkson BD (1987) MACOP-B for advanced diffuse intermediate and high grade Non-Hodgkin's lymphoma (NHL): preliminary results of the Memorial Hospital experience. Proc Am Soc Clin Oncol 6:201a
Kadin ME (1991) Ki-1-positive anaplastic large-cell lymphoma: a clinicopathologic entity? Clin Oncol 9, 533–536
McKinstry CS, Steiner RE, Young AT, Jones L, Swirsky D, Aber V (1987) Bone marrow in leukemia and aplastic anemia: MR imaging before, during and after treatment. Radiology 162:701–707
Miller PM, Dana BW, Weick JK, Jones SE, Coltman CA, Dahlberg S, Fisher RI (1988) Southwest Oncology Group clinical trials for intermediate- and high-grade Non-Hodgkin's lymphomas. Semin Hematol 25 [Suppl 2]:17–22
Nakamura S, Takagi N, Kojima M, Motoori T, Kitoh K, Osada H, Suzuki H, Ogura M, Kurita S, Oyama A, Ueda R, Takahashi T, Suchi T (1991) Clinicopathologic study of large cell anaplastic lymphoma (Ki-1-positive large cell lymphoma) among the Japanese. Cancer 68:118–129
Offit K, Ladanyi M, Gangi MS, Ebrahim SAD, Filippa D, Chaganti RSK (1990) Ki-1 antigen expression defines a favorable clinical subset of non-B cell non-Hodgkin's lymphoma. Leukemia 4:625–630
Oster W, Forsthuber T, Hennekeuser HH, Gamm H, Lindemann A, Schmitz G, Fuhr HG, Hinterberger R, Kreiter H, Thoenes W, Hermann F, Mertelsmann R (1990) MACOP-B chemotherapy for the treatment of high grade and intermediate grade Non-Hodgkin's lymphoma. Blut 60:23–27
Schneider AM, Straus DJ, Schluger AE, Löwenthal DA, Koziner B, Lee BJ, Wong G, Clarkson BD (1990) Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate- and some high-grade Non-Hodgkin's lymphomas. J Clin Oncol 8:94–102
Stein H (1988) The so-called Ki-1 lymphoma. Presented at the First Meeting of the European Association for Haematopathology, Geneva, Switzerland
Stein H, Mason DY, Gerdes J, O'Connor N, Wainscoat J, Pallesen G, Gatter K, Falini B, Delsal G, Lemke H, Schwarting R, Lennert K (1985) The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66:848–858
Vitolo U, Bertini M, Tarella C, Bertoncelli MC, Gallamini A, Gallo E, Gatti AM, Ghio R, Levis A, Luxi G, Marchi L, Novarino A, Orlandi E, Orsucci L, Riciutti F, Rota-Scalabrini D, Scassa E, Bernasconi C, Pileri A, Resegotti L (1989) MACOP-B treatment for advanced stage diffuse large cell lymphoma: a multicenter Italian study. Eur J Cancer Clin Oncol 25:1440–1449
Vogler JB III, Murphy WA (1988) Bone marrow imaging. Radiology 168:679–693
Weick J, Fisher RI, Dahlberg S, Hartsock R (1988) MACOP-B chemotherapy for NHL. A Southwest Oncology Group study (SWOG). Blood 66:249a
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Marosi, C., Heinz, R., Steger, G. et al. MACOP-B treatment in patients with Ki-1-positive large-cell anaplastic lymphoma. J Cancer Res Clin Oncol 118, 314–317 (1992). https://doi.org/10.1007/BF01208622
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01208622